New York is one of the only states in the U.S. that effectively bans direct-to-consumer lab testing, including popular at-home test kits sold by companies like Everlywell. The restriction comes down to a combination of strict laboratory permitting laws and a long-standing requirement that a licensed practitioner must order any clinical lab test. These rules predate the boom in online health testing, and despite growing pressure to modernize them, they remain largely unchanged.
The Practitioner Order Requirement
At the core of the restriction is a simple rule: in New York, a clinical laboratory test must be ordered by a qualified practitioner. That means a licensed physician, nurse practitioner, or other authorized provider has to formally request the test before a lab can run it. The order must be authenticated, either by a handwritten signature or a verified electronic signature tied to a unique identifier.
Most online lab testing companies work on a direct-to-consumer model. You pick a test, pay for it, collect a sample at home, and mail it to a lab. No doctor visit, no prescription, no practitioner involvement. That model directly conflicts with New York’s requirement. Even in states where some online platforms include a brief telehealth consultation to generate an order, New York’s regulatory framework treats the entire transaction with skepticism when it originates as a consumer purchase rather than a clinical decision.
New York’s Unusually Strict Lab Permitting System
New York also runs one of the most rigorous laboratory oversight programs in the country. Under Article 5, Title V of the state’s Public Health Law, any lab that processes specimens collected in New York must hold a state-issued clinical laboratory permit. This applies regardless of where the lab is physically located. A lab in Texas or California that receives a blood sample mailed from a New York address still needs a New York State Department of Health permit to legally analyze it.
The state’s Clinical Laboratory Evaluation Program, known as CLEP, enforces this through on-site inspections, proficiency testing reviews, and personnel evaluations. CLEP oversees more than 1,000 labs, including out-of-state facilities that accept New York specimens. The program’s stated goal is ensuring the accuracy and reliability of test results on specimens collected within the state. For online testing companies, getting a New York permit adds a layer of regulatory burden that many choose to avoid entirely. The result: companies like Everlywell simply don’t ship kits to New York addresses.
What This Looks Like in Practice
If you live in New York and try to order an at-home lab test from a major online provider, you’ll typically see a notice during checkout that the test is unavailable in your state. Everlywell, one of the largest players in the space, blocks all of its test kits from being shipped to New York. Other companies impose similar restrictions. The language is usually brief: “not available in New York due to state regulations.”
This doesn’t mean you can’t get lab work done. You can still get any test through the traditional route: visit a provider, have them order the test, and go to a lab for a blood draw or sample collection. New York also updated its rules in 2015 to allow patients to receive their lab results directly, which had previously required results to go through the ordering provider first. So the state has made some concessions toward patient access, just not in the direct-to-consumer testing space.
Why New York Takes This Approach
The reasoning behind the restrictions reflects a philosophy that lab testing should happen within the context of medical care, not outside it. Legislators and regulators have historically argued that a practitioner’s involvement serves as a safeguard: someone with clinical training decides which tests are appropriate, interprets the results, and follows up if something is abnormal. Without that layer, the concern is that consumers might order unnecessary tests, misinterpret results, or miss the clinical context that makes a result meaningful.
There’s also a quality control argument. New York’s permitting system predates the federal CLIA standards that most states rely on for lab oversight. The state has maintained its own, stricter program on the grounds that federal certification alone doesn’t guarantee the level of accuracy New York demands. For regulators, allowing test kits to bypass both the practitioner order and the state permitting process represents a double erosion of the oversight framework they’ve built.
The Specimen Collection Loophole
New York’s law applies to specimens “originating in” the state. This means the restriction is tied to where your sample is collected, not where you live. In theory, if you’re a New York resident traveling in another state and you collect a sample there, the specimen doesn’t originate in New York. Some consumers have used this as a workaround, though it’s not a practical everyday solution. The key legal trigger is the collection location, not your home address, but online testing companies generally use your shipping address to determine eligibility, which effectively blocks New York residents regardless.
Possible Changes Ahead
There is some legislative movement. A bill introduced in the New York State Assembly (A10125) during the 2025-2026 session would exempt “waived tests” from the state’s clinical laboratory requirements entirely. Waived tests are simple, low-risk tests that the federal government considers unlikely to produce erroneous results, a category that includes many of the tests sold in at-home kits, like basic cholesterol checks and certain hormone panels. The bill was referred to the Assembly Health Committee in early 2026 and has not yet advanced further.
If passed, the bill would remove waived tests from the permitting and oversight requirements of Title V, potentially opening the door for at-home testing companies to ship to New York. But the bill’s language is narrow, and it remains in the early stages of the legislative process. For now, New York’s restrictions remain fully in effect, making it the most significant holdout state for the online lab testing industry.